Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Gossamer Bio Inc(GOSS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GOSS
09/28/2026: GOSS (1-star) is currently NOT-A-BUY. Pass it for now.
Gossamer Bio is a clinical-stage biotechnology company focused on developing proprietary, novel therapies for pulmonary and immunology-based diseases. Its primary value rests on the success of its lead candidate, seralutinib, which is designed to improve treatment options for pulmonary arterial hypertension. The firm's main strength is its specialized R&D platform and experienced management, while its primary risk remains the high uncertainty of clinical trial outcomes and the necessity for continued capital funding. This stock is best suited for growth-oriented investors with a high risk tolerance who are specifically looking to monitor the progress of clinical milestones and potential regulatory approvals.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The stock fits a growth profile based on potential innovation but lacks the revenue history typical of mature growth stocks. |
| Momentum investor | Strong fit while signal remains positive | Biotech stocks often experience high momentum around clinical data releases, making it suitable for those watching for technical upturns. |
| Value investor | Weak fit | The lack of earnings and clinical-stage status makes it unsuitable for traditional valuation-based metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology is inherently high-risk, making it inappropriate for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant price swings based on clinical trial outcomes and biotech sentiment. |
| Valuation risk | High | Valuations are speculative and sensitive to investor perception of the pipeline's future potential. |
| Competition risk (Pharma incumbents) | High | Established players possess the resources to dominate the market with existing therapies. |
| Business quality | Medium | While the scientific team is strong, the lack of commercialized products limits current business quality. |
| Dividend income | Low / none | Income investors should not look to GOSS for yield. |
| Execution risk | High | The company must navigate complex clinical and regulatory pathways successfully to survive. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 39.54% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 66.91M USD | Price to earnings Ratio - | 1Y Target Price 82.48 |
Price to earnings Ratio - | 1Y Target Price 82.48 | ||
Volume (30-day avg) 307.5K shares | Beta 2 | 52 Weeks Range 9.12 - 309.60 | Updated Date 09/27/2026 |
52 Weeks Range 9.12 - 309.60 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -52.73 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and development of proprietary therapeutics. | The company is currently burning cash to develop new drugs and does not generate revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49.99M | Price to Sales(TTM) 1.26 |
Enterprise Value 49.99M | Price to Sales(TTM) 1.26 | ||
Enterprise Value to Revenue 0.94 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 6.12M | Shares Floating 3.83M |
Shares Outstanding 6.12M | Shares Floating 3.83M | ||
Percent Insiders 1.43 | Percent Institutions 85.73 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Gossamer Bio Inc
Exchange NASDAQ | Headquarters San Diego, CA, United States | ||
IPO Launch date 2019-02-08 | Co-Founder, CEO, President & Chairman Mr. Faheem Hasnain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 161 | Website https://www.gossamerbio.com |
Full time employees 161 | Website https://www.gossamerbio.com | ||
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.